Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.
April 08, 2025 11:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting

Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology A
March 27, 2025 08:30 ET | Source: Chemomab Therapeutics

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.
March 11, 2025 08:30 ET | Source: Longeveron

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.
December 09, 2024 04:00 ET | Source: AKAMPION

tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients

- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
December 06, 2024 12:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet
December 02, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
November 19, 2024 07:00 ET | Source: Chemomab Therapeutics

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC
November 19, 2024 04:44 ET | Source: Research and Markets

Clinical Data Analytics Solutions Market Forecast to 2034 by Solution, Application, End-user and Region, Featuring Exhaustive Company Profiles of 10+ Major Players

Dublin, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The "Clinical Data Analytics Solutions Market by Solution, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
November 05, 2024 09:00 ET | Source: ImCheck Therapeutics SAS

ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer

ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer Marseille, France, November 5, 2024, 3 pm CET – ImCheck Therapeutics...

Next Page keyboard_arrow_right